التجارب السريرية بالأسفل التجارب السريرية الحالية.98 دراسات في طب الجهاز الهضمي والكبد (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers Rochester, Minn. A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers. Influence of Diet on Tissue and Body Fluids in Health and Disease Scottsdale/Phoenix, Ariz. This study aims to compare the fatty acid composition of small sample of fat (visceral and subcutaneous) removed at the time of surgery to operative outcomes and the composition calculated from the person’s dietary history and preoperative imaging with MRI/CT scans. This study will also compare the composition of pancreatic fluid collected to that of a sample of fat removed at the time of surgery to drain the collection. Furthermore, we will study the fatty acid composition of drain fluid placed at the time of surgery to that of their fat samples. SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Rochester, Minn. The purpose of this interventional study is to test and compare the effectiveness of two elimination diets—the 1-food elimination diet (1FED, milk only) and the 6-food elimination diet (6FED, milk, egg, wheat, soy, tree nut/peanuts, and fish/shellfish). The study will also test the effectiveness of swallowed glucocorticoid therapy in some of the study participants for whom diet therapy was not effective. A Study to Evaluate the Prevalence and Impact of Eating Disorders Among Patients with Inflammatory Bowel Disease Jacksonville, Fla. The purpose of this study is to assess the prevalence of eating disorders; specifically, Avoidant/Restrictive Food Intake Disorder (ARFID) among adult patients in the IBD clinic and compare to the patient population seen in the primary care clinics at Mayo Clinic Florida. A Study to Assess a New Personalized Tool for Colorectal Cancer Peritoneal Disease Treatment Rochester, Minn. The objectives of this study are to genomically characterize patient-derived organoids (PDOs) and primary tissues from colorectal peritoneal cancer (CRC) disease, to evaluate the use of PDOs as a new personalized therapy selection tool for intraperitoneal therapy in CRC peritoneal disease, and to evaluate the use of PDOs as a new personalized therapy selection tool for systemic therapy in CRC peritoneal disease. A Quality of Life Assessment of Patients with Biliary Obstruction Undergoing Endoscopic or Percutaneous Drainage Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The aim of this study is to compare the quality of life of patients with biliary obstruction who have undergone an endoscopic or percutaneous drainage. The quality of life of patients witll be assessed using the validated "European Quality of Life-5 Dimensions Questionnaire" and the "Intervention-Dependent Questionnaire" which was developed according to current literature as well as the expert opinion of gastroeneterologists. A Study to Evaluate Intra-arterial Delivery of Mesenchymal Stem Cells for Luminal Ulcerative Colitis Rochester, Minn. Ulcerative Colitis (UC) is a chronic inflammatory disease affecting the mucosal lining of the colon and rectum and the incidence is increasing, but the etiology remains unknown. Patients may require a proctocolectomy due to refractory disease. Prior to an operation, UC is treated with antibiotic therapy, immunomodulatory therapy and immunosuppressive agents. While there is an increasing number of approved biologics for the treatment of UC, there are many patients that still suffer from refractory disease. Thus, alternative mechanisms of therapy are desperately needed. Treatments that have the potential to reduce mucosal inflammation could alleviate the pathology of luminal UC. This trial will use arterially delivered mesenchymal stem cells (MSCs) to produce these regenerative signals allowing for mucosal healing. This study will enroll patients with medically refractory moderate to severe inflammatory UC who are or plan to be scheduled for a colectomy. Patients enrolled will be those who failed all attempts at standard treatment including antibiotics, corticosteroids, immunomodulator, and/or biologic therapy. Participants will undergo screening for study, if eligible, participants will be dosed with 15 million or 30 million cells will be administered via IA delivery with interventional radiology. Participant study visits after study intervention includes visits on: Day 1, Week 1, Week 2, Week 8, Week 24, Week 52, and Week 104. A Study to Evaluate Ramucirumab Plus Trifluridine/Tipiracil to Treat Patients with Previously-treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to compare, in a non-inferiority fashion, the progression-free survival (PFS) in patients with metastatic refractory gastric/Gastroesophageal Junction (GEJ) adenocarcinoma receiving the combination of ramucirumab with TAS-102 vs. paclitaxel and ramucirumab. A Study to Examine Financial Distress in Patients Undergoing Treatment of Locally-advanced Rectal Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to examine the needs and gap in our understanding of financial burden experienced by rectal cancer patients from a patient perspective to help provide patient centered care and improve psychosocial outcomes of this group. A Study to Evaluate Encorafenib Plus Cetuximab with/without Chemotherapy to Treat Metastatic Colorectal Cancer Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of care chemotherapy in participants with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 77 توجّه للصفحة 88 توجّه للصفحة 99 توجّه للصفحة 1010 التاليالصفحة التالية طلب تحديد موعد الخبرة و مراتب التصنيفالأبحاث 30/05/2024 صُنفت مايو كلينك في روتشستر بولاية مينيسوتا كأفضل مستشفى في طب الجهاز الهضمي وجراحته على المستوى الوطني حسب بيانات 2024-2025 الصادرة عن U.S. News & World Report. اعرف المزيد عن هذا الشرف الرفيع طب الجهاز الهضمي والكبدالقسمالرئيسيالأقساممُلخّصالاختبارات والتشخيصالحلات التي يتم علاجهاالأطباءالأطباء حسب الموقع والتخصصالمجموعات المتخصصةالخبرة و مراتب التصنيفالتجارب السريريةالأبحاثقصص المرضىالتكاليف والتأمين الصحيالأخبار من Mayo Clinicإحالةالمرضى الأبحاث: المرضى محور اهتمامنا إظهار النسخة النصية للفيديو الأبحاث: المرضى محور اهتمامنا [عزف موسيقي] جوزيف سيرفين، دكتور في الطب، أستاذ طب الأعصاب في مايو كلينك: تتمثّل مهمة مايو في رعاية المريض. فمصلحة المريض أولًا. ولذلك فإن مهمّتنا وأبحاثنا تهدف إلى إحراز التقدّم في طريقة الاعتناء بالمريض، وتقديم مصلحته على كل الجوانب الأخرى من الرعاية. وهذا من عدة أوجه أقرب إلى دورة متعاقبة المراحل. فالأمر يبدأ بفكرة بسيطة ثبت نجاحها في المختبر، ثم طُبِّقت على المريض في سريره، وإذا سار كل شيء على ما يرام -بمعنى أنها كانت مفيدة له- فإننا نعتمدها على أنها نهج قياسي. وهذا في رأيي واحد من السمات الفريدة التي تميّز نهج مايو كلينك في البحث -أعني التركيز على المريض- وهو يساعد بحق في تمييزه عمّا سواه. الأقسامطلب موعدمُلخّصالاختبارات والتشخيصالحلات التي يتم علاجهاالأطباءالأطباء حسب الموقع والتخصصالمجموعات المتخصصةالخبرة و مراتب التصنيفالتجارب السريريةالأبحاثقصص المرضىالتكاليف والتأمين الصحيالأخبار من Mayo Clinicإحالة المرضى ORG-20308333 الأقسام والمراكز الطبية طب الجهاز الهضمي والكبد